Back to results
US 2020/0002415 A1Published application
Binding molecules specific for fcgamma riia and uses thereof
AssigneeViela Bio, Inc.
InventorsKatherine Ann Vousden, Bo Chen, Gary Patrick Sims
Life of this patent
Estimating the term…
Abstract
The disclosure provides FcγRIIA-binding molecules, for example, humanized monoclonal antibodies capable of inhibiting FcγRIIA activity, and methods of using the FcγRIIA binding molecules, for example, in treating or preventing inflammatory, immune-mediated, or autoimmune diseases or disorders.
Claims29
An isolated binding molecule that specifically binds to FcγRIIA, wherein the binding molecule comprises:
- a. an immunoglobulin variable heavy chain complementarity determining region 2 (VH-CDR2) and an immunoglobulin variable light chain complementarity determining region 1 (VL-CDR1) comprising amino acid sequences selected from the group consisting of:
- (i) SEQ ID NO:
- 19 and SEQ ID NO:
- 22;
- (ii) SEQ ID NO:
- 19 and SEQ ID NO:
- 23;
- (iii) SEQ ID NO:
- 19 and SEQ ID NO:
- 24;
- (iv) SEQ ID NO:
- 20 and SEQ ID NO:
- 25;
- (v) SEQ ID NO:
- 20 and SEQ ID NO:
- 23;
- and (vi) SEQ ID NO:
- 20 and SEQ ID NO:
- 26, respectively;
- b. an immunoglobulin variable heavy chain complementarity determining region 1 (VH-CDR1) comprising SEQ ID NO:
- 29;
- c. an immunoglobulin variable heavy chain complementarity determining region 3 (VH-CDR3) comprising SEQ ID NO:
- 30 or SEQ ID NO:
- 45;
- d. an immunoglobulin variable light chain complementarity determining region 2 (VL-CDR2) comprising SEQ ID NO:
- 31;
- and
- e. an immunoglobulin variable light chain complementarity determining region 3 (VL-CDR3) comprising SEQ ID NO:
- 32.
26 more elements
(canceled)
7-8. (canceled)
(canceled)
13-17. (canceled)
(canceled)
24-25. (canceled)
(canceled)
(canceled)
33-34. (canceled)
36-37. (canceled)
Dependencies are inferred from the claim text.